Health Care [ 2/12 ] | Biotechnology [ 13/75 ]
NASDAQ | Common Stock
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada.
It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney.
The company is based in Calgary, Canada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 2, 26 | -0.10 Increased by +88.26% | -0.32 Increased by +69.91% |
| Nov 13, 25 | -0.13 Increased by +33.88% | -0.32 Increased by +57.69% |
| Aug 15, 25 | -0.19 Decreased by -424.23% | - |
| May 14, 25 | 0.04 Decreased by -97.04% | - |
| Mar 25, 25 | -0.81 Decreased by -27.36% | -0.41 Decreased by -97.56% |
| Nov 12, 24 | -0.20 Increased by +69.82% | - |
| Aug 14, 24 | 0.06 Increased by +107.33% | -0.92 Increased by +106.35% |
| May 15, 24 | 1.35 Increased by +1.33 K% | -0.28 Increased by +588.04% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 0.00 Decreased by N/A% | -822.64 K Decreased by -790.86% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -642.27 K Decreased by -8.54% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -729.52 K Decreased by -529.06% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -696.56 K Increased by +76.82% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | 119.08 K Decreased by -95.71% | Increased by +N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -591.73 K Increased by +55.05% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | 170.03 K Increased by +109.92% | Increased by +N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -3.01 M Decreased by -64.04% | Decreased by N/A% Decreased by N/A% |